Effect of the number of cycles of docetaxel + S-1 therapy on long-term survival in adjuvant chemotherapy for stage III gastric cancer. A pooled analysis of the OGSG0604 and OGSG1002 trials
ConclusionAlthough eight cycles of DS therapy may prolong prognosis, the present study did not provide a clear conclusion as to how many DS therapy cycles are needed to improve prognosis after D2 gastrectomy for stage III gastric cancer.Trial registrationRegistration number: UMIN00000714 and UMIN000004440.
Source: Gastric Cancer - Category: Gastroenterology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Gastrectomy | Gastric (Stomach) Cancer | Gastroenterology | Japan Health | Study | Taxotere